SF1126, a Pan-PI3K inhibitor has potent pre-clinical activity in aggressive B-cell non-Hodgkin lymphomas by inducing cell cycle arrest and apoptosis

Keyphrases

• Apoptosis 100%
• Cell Cycle Arrest 100%
• Clinical Activity 100%
• Aggressive B-cell non-Hodgkin Lymphoma 100%
• PI3K Inhibitor 100%
• SF1126 100%
• Cell Proliferation 40%
• Solid Tumors 20%
• Lymphoma Cells 20%
• Rituximab 20%
• B-cell non-Hodgkin Lymphoma (B-NHL) 20%
• B-cell NHL 20%
• CAL-101 20%
• Prodrug 10%
• Dose Effect 10%
• Induced Apoptosis 10%
• PI3K-Akt Pathway 10%
• Cell Cycle Progression 10%
• IC50 10%
• Mechanism of Action 10%
• Cyclin D1 (CCND1) 10%
• Lymphoma 10%
• Novel Therapeutics 10%
• Leukemia 10%
• Akt Phosphorylation 10%
• G1 Cell Cycle Arrest 10%
• LY294002 10%
• Clinical Testing 10%
• Glycogen Synthase Kinase 3 (GSK3) 10%
• Clinical Trial Evaluation 10%
• Human Tumors 10%
• Early Phase Clinical Trials 10%
• PI3K Pathway 10%
• RGD Peptide 10%
• P110 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Nonhodgkin Lymphoma 100%
• [1 (4 Oxo 8 Phenyl 4h 1 Benzopyran 2 Yl)morpholinio]methoxysuccinylarginylglycylaspartylserine Acetate 100%
• Solid Malignant Neoplasm 20%
• Rituximab 20%
• Prodrug 10%
• Neoplasm 10%
• IC50 10%
• Clinical Trial 10%
• Cyclin D1 10%
• Leukemia 10%
• Glycogen Synthase Kinase 10%
• 2 Morpholino 8 Phenylchromone 10%